Source: International Congress 2016 – Clinical update on bronchiectasis
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Anthony De Soyza (Newcastle-upon-Tyne, United Kingdom), Anthony De Soyza, Timothy Aksamit, Tiemo-Joerg Bandel, Margarita Criollo, J. Stuart Elborn, Ulrike Krahn, Elisabeth Operschall, Eva Polverino, Kevin Winthrop, Robert Wilson. LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB). Eur Respir J 2016; 48: Suppl. 60, 272

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002 3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010 Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008 12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i.diskus) as first-line regular asthma treatment Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003 Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Fluticasone propionate 100μg bd (FP100) has significantly less effect than budesonide 200μg bd (BUD200) on childhood growth over 1 year of treatment in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002 Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 3x2g ceftazidime as short infusion versus 2x2g ceftazidime as 7 hours infusion in patients with acute exacerbation of severe chronic bronchitis (AECB) Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Salmeterol 50μg b.i.d. significantly increases though fev1 in COPD up to 12 months without loss of effect Source: Eur Respir J 2003; 22: Suppl. 45, 376s Year: 2003 Effect of codeine (30mg) with paracetamol (650mg) on post bronchoscopy coughing –an open labeled placebo control trial Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019 Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Low-dose (100 μg, b.i.d.) inhaled fluticasone propionate (FP) is as effective as high-dose (500 μg, b.i.d.) in mild symptomatic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Evaluation of tiotropium rotacaps once daily in patients with chronic obstructive pulmonary disease over 4 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005 Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 457s Year: 2007